Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
نویسندگان
چکیده
Robert HI Andtbacka, Huntsman Cancer Institute Frances A. Collichio, University of North Carolina at Chapel Hill Thomas Amatruda, Minnesota Oncology Neil Senzer, Mary Crowley Cancer Research Center Jason Chesney, University of Louisville Keith Delman, Emory University Lynn Spitler, Northern California Melanoma Center Igor Puzanov, Vanderbilt University Medical Center Sanjiv Agarwala, St. Luke's University Hopsital Mohammed Milhem, University of Iowa
منابع مشابه
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
Background T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate within tumors, produce GM-CSF and enhance systemic antitumor immune responses. In OPTiM (NCT00769704), a randomized Phase III trial of intralesional T-VEC vs subcutaneous GM-CSF for unresected stage IIIB-IV melanoma, TVEC significantly improved DR rate (partial response or complete response lasting co...
متن کاملEfficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
OBJECTIVES Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage colony-stimulating factor (GM-CSF) in 436 patients with unresectable stage IIIB-IVM1c melanoma. T...
متن کاملCutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
BACKGROUND Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating facto...
متن کاملTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
PURPOSE Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III tri...
متن کاملA Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) Georgina V Long, Reinhard Dummer, Antoni Ribas, Igor Puzanov, Olivier Michielin, Ari VanderWalde, Robert HI Andtbacka, Jonathan Cebon, Eugenio Fernandez, Josep Malvehy, Anthony J Olszanski, Thomas F Gajewski, J...
متن کامل